Treatment
Omalizumab clinical trials
We’re tracking 13 recruiting studies that include Omalizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05916937RecruitingPhase 4
Test longer dosing of omalizumab for chronic hives
This Phase 4 study looks at whether extending the time between omalizumab injections can still control chronic spontaneous hives (CSU). It may help some people need fewer injections while keeping symptoms under control.
Copenhagen, Copenhagen NAges 18 years+ - NCT06943534RecruitingPhase 2
Omalizumab for severe food allergies: weight-based dosing study
This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.
Boston, MassachusettsAges 1–55 - NCT05332067RecruitingPhase 2
Omalizumab to prevent future asthma flare-ups before they start
This trial studies whether starting omalizumab before asthma flare-ups begin can reduce how often children get worsening asthma that needs strong steroid medicine. It is for children with persistent asthma who have signs of allergic/asthma triggers and recent flare-up history.
Washington D.C., District of ColumbiaAges 6–17 - NCT06618963RecruitingPhase 4
Omalizumab for food allergy skin effects
This trial tests if omalizumab (Xolair) can improve skin reactions in people with food allergies. It may help reduce allergic symptoms triggered by foods like peanut, egg, or milk.
Denver, ColoradoAges 1–55 - NCT06934200RecruitingPhase 2
Xolair for food allergy in people with high IgE
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
Baltimore, MarylandAges 1–55 - NCT07059091RecruitingPhase 2
Omalizumab for COPD with allergies
This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.
Birmingham, AlabamaAges 40 years+ - NCT07425639Recruiting
Switching From Omalizumab to OMLYCLO in Asthma or Hives
This study follows patients with severe asthma or chronic hives who are already on omalizumab (Xolair) and are switching to a very similar, lower-cost biosimilar called OMLYCLO. It aims to see if the switch works well in real-world practice.
MontpellierAges 18 years+ - NCT06683261Recruiting
Real-world study of biologics for nasal polyps
This study follows people with chronic rhinosinusitis and nasal polyps who are starting a biologic medication (omalizumab, mepolizumab, or dupilumab) to see how well it works in real life.
AalstAges 18 years+ - NCT07356713RecruitingPhase 1
Finding the right dose of EXL-111 for healthy volunteers
This trial tests a new drug called EXL-111 in healthy people to find the safest and best dose for future studies. It may help people with allergies if the drug proves effective.
Adelaide, South AustraliaAges 18–55 - NCT07342803RecruitingPhase 2
LP-003 injection for allergic asthma
This trial tests an injection called LP-003 for people with allergic asthma that is not well controlled by current inhalers and other medications. It aims to see if the drug can improve asthma control and reduce flare-ups.
ShanghaiAges 18–75 - NCT04763447RecruitingPhase 4
Short omalizumab treatment for severe allergic asthma
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
Paris, Île-de-France RegionAges 18 years+ - NCT06509334RecruitingPhase 2
Study of JYB1904 for chronic hives
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07431658Enrolling by invitation
Diet and stress effects on omalizumab response in chronic hives
This study looks at how diet and oxidative stress (a type of cell damage) affect the severity of chronic hives and how well patients respond to the medication omalizumab (Xolair). It may help find ways to improve treatment by understanding these factors.
IstanbulAges 18–65
What Omalizumab is being studied for
Conditions with recruiting Omalizumab studies.
Common questions
- Are there clinical trials studying Omalizumab?
- Yes. Clin2 currently lists 13 recruiting studies that include Omalizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Omalizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Omalizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Omalizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.